These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37380634)

  • 1. DprE2 is a molecular target of the anti-tubercular nitroimidazole compounds pretomanid and delamanid.
    Abrahams KA; Batt SM; Gurcha SS; Veerapen N; Bashiri G; Besra GS
    Nat Commun; 2023 Jun; 14(1):3828. PubMed ID: 37380634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delamanid or pretomanid? A Solomonic judgement!
    Mudde SE; Upton AM; Lenaerts A; Bax HI; De Steenwinkel JEM
    J Antimicrob Chemother; 2022 Mar; 77(4):880-902. PubMed ID: 35089314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations in
    Rifat D; Li SY; Ioerger T; Shah K; Lanoix JP; Lee J; Bashiri G; Sacchettini J; Nuermberger E
    Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33077652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptional profiling of a laboratory and clinical Mycobacterium tuberculosis strain suggests respiratory poisoning upon exposure to delamanid.
    Van den Bossche A; Varet H; Sury A; Sismeiro O; Legendre R; Coppee JY; Mathys V; Ceyssens PJ
    Tuberculosis (Edinb); 2019 Jul; 117():18-23. PubMed ID: 31378263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis.
    Wen S; Jing W; Zhang T; Zong Z; Xue Y; Shang Y; Wang F; Huang H; Chu N; Pang Y
    Eur J Clin Microbiol Infect Dis; 2019 Jul; 38(7):1293-1296. PubMed ID: 30953211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and preclinical evaluations of JBD0131, a novel nitrodihydro-imidazooxazole anti-tuberculosis agent.
    Luo W; Huang Z; Xu D; Yang M; Zhu Y; Shen L; Chen S; Tao X; Bin W; Hu Y; Franzblau SG; Jiang N; Wei Y; Wei X; Ding CZ
    Bioorg Med Chem Lett; 2022 Sep; 72():128871. PubMed ID: 35777718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting nitroimidazole antibiotic resistance mutations in Mycobacterium tuberculosis with protein engineering.
    Lee BM; Harold LK; Almeida DV; Afriat-Jurnou L; Aung HL; Forde BM; Hards K; Pidot SJ; Ahmed FH; Mohamed AE; Taylor MC; West NP; Stinear TP; Greening C; Beatson SA; Nuermberger EL; Cook GM; Jackson CJ
    PLoS Pathog; 2020 Feb; 16(2):e1008287. PubMed ID: 32032366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Progress in the Discovery and Development of 2-Nitroimidazooxazines and 6-Nitroimidazooxazoles to Treat Tuberculosis and Neglected Tropical Diseases.
    Showalter HD
    Molecules; 2020 Sep; 25(18):. PubMed ID: 32927749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR Screening and Comparative LC-MS Analysis Identify Genes Mediating Efficacy of Delamanid and Pretomanid against Mycobacterium tuberculosis.
    Yan MY; Li H; Qu YM; Li SS; Zheng D; Guo XP; Wu Z; Lu J; Pang Y; Li W; Yang J; Zhan L; Sun YC
    Adv Sci (Weinh); 2024 Aug; ():e2400176. PubMed ID: 39162029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radical Releasing Anti-tuberculosis Agents and the Treatment of
    Kareem AI; Malan SF; Joubert J
    Mini Rev Med Chem; 2022; 22(2):387-407. PubMed ID: 33605858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The
    Mansjö M; Karlsson Lindsjö O; Grönfors Seeth C; Groenheit R; Werngren J
    Antimicrob Agents Chemother; 2022 Dec; 66(12):e0102622. PubMed ID: 36409105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
    Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
    Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DprE1--from the discovery to the promising tuberculosis drug target.
    Mikusová K; Makarov V; Neres J
    Curr Pharm Des; 2014; 20(27):4379-403. PubMed ID: 24245764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assay development and inhibition of the
    Batt SM; Toth S; Rodriguez B; Abrahams KA; Veerapen N; Chiodarelli G; Cox LR; Moynihan PJ; Lelievre J; Fütterer K; Besra GS
    Microbiology (Reading); 2023 Jan; 169(1):. PubMed ID: 36748627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretomanid resistance: An update on emergence, mechanisms and relevance for clinical practice.
    Nguyen TVA; Nguyen QH; Nguyen TNT; Anthony RM; Vu DH; Alffenaar JC
    Int J Antimicrob Agents; 2023 Oct; 62(4):106953. PubMed ID: 37595848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid.
    Kadura S; King N; Nakhoul M; Zhu H; Theron G; Köser CU; Farhat M
    J Antimicrob Chemother; 2020 Aug; 75(8):2031-2043. PubMed ID: 32361756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and evaluation of pretomanid (PA-824) oxazolidinone hybrids.
    Rakesh ; Bruhn DF; Scherman MS; Singh AP; Yang L; Liu J; Lenaerts AJ; Lee RE
    Bioorg Med Chem Lett; 2016 Jan; 26(2):388-391. PubMed ID: 26711150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Expanding Diversity of Mycobacterium tuberculosis Drug Targets.
    Wellington S; Hung DT
    ACS Infect Dis; 2018 May; 4(5):696-714. PubMed ID: 29412643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delamanid Resistance: Update and Clinical Management.
    Nguyen TVA; Anthony RM; Cao TTH; Bañuls AL; Nguyen VAT; Vu DH; Nguyen NV; Alffenaar JC
    Clin Infect Dis; 2020 Dec; 71(12):3252-3259. PubMed ID: 32521000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adduct Formation of Delamanid with NAD in Mycobacteria.
    Hayashi M; Nishiyama A; Kitamoto R; Tateishi Y; Osada-Oka M; Nishiuchi Y; Kaboso SA; Chen X; Fujiwara M; Inoue Y; Kawano Y; Kawasaki M; Abe T; Sato T; Kaneko K; Itoh K; Matsumoto S; Matsumoto M
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.